The role of apoptosis in acute lung injury
Thomas R. Martin, MD; Morio Nakamura, MD; Gustavo Matute-Bello, MD I n humans, acute lung injury (ALI) is associated with disruption of the alveolar epithelium, epithelial basement membrane, and microvascular endothelium, resulting in a major increase in microvascular and epithelial permeability in the lungs (1) . The resultant flooding of the interstitial and intra-alveolar compartments causes severe ventilation/perfusion mismatching with life-threatening hypoxemia.
A great deal of emphasis has been placed on the role of inflammatory cells in the pathogenesis of endothelial and epithelial injury in ALI. However, recent evidence about shear forces generated during mechanical ventilation, and the activation of apoptosis pathways in the lungs of patients with ALI, has focused interest on other mechanisms of endothelial and epithelial injury in humans.
Apoptosis
Apoptosis is a process of controlled cell death, which is important in the development of tissues and in the remodeling of tissues that occurs during normal repair processes. Apoptosis can be triggered by environmental conditions or by specific receptor-ligand interactions. Receptor-dependent apoptosis is controlled by a series of surface receptors in the tumor necrosis factor-receptor family. These activate intracellular signaling pathways that lead to DNA cleavage and cell death (2, 3) .
Apoptosis is accompanied by condensation of nuclear material and the cytoplasmic contents, so that intracellular products are not spilled into the extracellular space. In contrast, cell death by necrosis is associated with disruption of the cell membrane and the release of intracellular proteases and other constituents into the extracellular milieu. During development, apoptosis occurs without corresponding inflammation in the adjacent tissue. In contrast, necrosis often is associated with the activation of inflammatory pathways in the surrounding environment.
Signaling Pathways. Apoptosis signaling pathways are activated in response to receptor-ligand interactions, environmental factors (such as ultraviolet light and changes in oxidation/reduction potential), and internal factors encoded in the genome ("programmed cell death"). Inappropriate activation or inhibition of these pathways can lead to disease, either because cells have prolonged survival (malignant transformation) or because they die prematurely and produce structural changes in normal tissue (e.g., apoptosis of lung epithelial cells).
Apoptosis pathways are modulated by cytokines and other products in the inflammatory milieu, with results that differ depending on the cell type. At inflammatory sites in the lungs, neutrophil apoptosis is delayed and epithelial apoptosis is enhanced. Because apoptosis is a regulated event, new therapeutic interventions that inhibit key steps in the apoptosis pathways hold promise for limiting some types of injury responses in the lungs.
Neutrophil Apoptosis in ALI
Neutrophilic inflammation in the alveolar spaces is the hallmark of ALI in humans and is characteristic of most animal models of ALI. At the onset of sepsis in experimental models, circulating neutrophils undergo changes in deformability that cause them to be trapped in the small capillaries of the pulmonary microcirculation. The trapped neutrophils respond to local chemokine gradients produced by alveolar macrophages in response to bacterial stimuli in the airspaces (4). C-X-C chemokines, such as interleukin (IL)-8, growth-related oncogene product, and epithelial cell-derived neutrophil-activating protein-78, estab-lish stable tissue gradients that direct neutrophil migration into the lungs. Other constituents of the alveolar inflammatory milieu, such as granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF), modulate neutrophil and neutrophil-macrophage function, respectively. Neutrophils reach the airspaces in a functional state and undergo metabolic activation and respiratory burst activity in response to bacterial stimuli in the airspaces (5, 6) .
Apoptosis of Neutrophils. Neutrophil apoptosis may be beneficial or harmful, because shortened neutrophil lifespan could minimize the release of neutrophil oxidants and enzymes but at the same time reduce the microbicidal activity of airspace neutrophils. Neutrophils are relatively short-lived cells, and large numbers accumulate in the airspaces in ALI, posing a major challenge for the host in resolving inflammation. Neutrophils obtained from human blood rapidly undergo apoptosis when incubated in buffered solutions ex vivo. During apoptosis, neutrophils undergo characteristic changes, including nuclear condensation with the development of apoptotic bodies and coalescence of the cytoplasmic contents. Therefore, it initially was thought that apoptotic neutrophils would be easy to identify at sites of inflammation in vivo. However, cytospin slides of lung leukocytes obtained by bronchoalveolar lavage (BAL) from patients with ALI showed that apoptotic neutrophils were very rare, accounting for Ͻ10% of neutrophils in the BAL fluid (7) .
As apoptosis progresses, granular enzymes are not released. Phosphatidylserine residues on the inner leaflet of the cell membrane are externalized, providing a marker that can be detected by the binding of annexin V. Studies using electron microscopy and flow cytometry with annexin V binding confirmed the visual observation that apoptotic neutrophils are rare in cell populations from the lungs of patients with acute respiratory distress syndrome (ARDS) (7). More than 30% of alveolar macrophages in electron microscopic images contained evidence of neutrophil nuclei or granules, suggesting that they had ingested apoptotic polymorphonuclear neutrophils in vivo.
BAL Fluid. Apoptosis can be delayed by factors such as GM-CSF. When normal human neutrophils were incubated in the BAL fluid of patients with ARDS, apoptosis was delayed, suggesting that BAL fluid contains factors that prolong the lifespan of neutrophils. The analysis of BAL fluid from patients with ARDS revealed high concentrations of G-CSF and GM-CSF (8) . Inhibiting GM-CSF with specific monoclonal antibodies removed nearly all of the apoptosis-inhibitory activity of ARDS BAL fluid, supporting the conclusion that colony-stimulating factors prolong neutrophil life at sites of pulmonary inflammation.The inhibitory effect of BAL fluid declined at later stages of ARDS, paralleled by a decline in GM-CSF concentration. Patients who survived ARDS tended to have higher concentrations of GM-CSF in BAL fluids, suggesting that prolongation of neutrophil life in the airspaces could be beneficial in some cases (8) , such as in ALI associated with bacterial infections in the lungs or systemic circulation.
Evidence from animal studies supports a delay in neutrophil apoptosis. Parsey et al. (9) measured the proportion of apoptotic neutrophils in the lungs of mice for 48 hrs after endotoxemia or hemorrhage. Immediately after hemorrhage or induction of endotoxemia, the proportion of apoptotic neutrophils in lung fluids was 18.5 Ϯ 1.9%. This proportion declined to 6 -7% as early as 1 hr after hemorrhage or endotoxemia and remained low for Ͼ24 hrs.
Neutrophil Clearance. Apoptotic neutrophils are cleared from the lungs by macrophages and other phagocytic cells, which recognize apoptotic neutrophils via membrane surface molecules. In ARDS, macrophages ingest apoptotic neutrophils at a very rapid rate, which may partly account for the low number of apoptotic neutrophils seen in vivo. The macrophage CD44 receptor appears to play an important role in the clearance of apoptotic neutrophils in vivo and in vitro (10, 11) . Using a model of bleomycininduced lung injury, Teder et al. (10) showed that CD44-deficient mice failed to clear apoptotic neutrophils from the lungs. This failure was associated with greater inflammation and increased mortality rate. Adoptive transfer of normal marrow cells into the CD44-deficient mice accelerated the clearance of apoptotic neutrophils and improved survival. Hussein et al. (12) also demonstrated that the rate of clearance of apoptotic neutrophils is important in the resolution of lung injury. Using an oleic acid model of lung injury in rats, these authors showed that neutrophils became apoptotic during resolution of lung injury and that apoptotic neutrophils were taken up by alveolar macrophages in vivo.
Phagocytosis by Macrophages. The phagocytosis of apoptotic neutrophils by alveolar macrophages is associated with a change in the anti-inflammatory macrophage phenotype. Phagocytosis of apoptotic neutrophils inhibits macrophage production of IL-1␤, IL-8, IL-10, GM-CSF, and tumor necrosis factor-␣ and increases the production of the anti-inflammatory mediators transforming growth factor (TGF)-␤1 and prostaglandin E2 (13, 14) . These observations support the concept that the ingestion of apoptotic neutrophils by macrophages favors the resolution of inflammation in the lungs.
Summary. Neutrophils undergo apoptosis in the airspaces and are rapidly ingested by alveolar macrophages. Neutrophil apoptosis is delayed early in the course of ARDS by cytokines in the alveolar milieu, and the relationship between prolonged neutrophil half-life in the lungs and continuing lung injury remains to be clarified.
Epithelial Apoptosis in ALI
In addition to acute neutrophilic alveolitis, hallmarks of ARDS in humans include destruction of the alveolar epithelium and damage to the alveolar capillary endothelium.
Epithelial Function. Clinical studies have shown that epithelial function is impaired in patients with ARDS, and intact epithelial function is associated with an improved outcome (15, 16) . The alveolar epithelium is a tight barrier that normally restricts the movement of proteins and fluid from the interstitium to the alveolar spaces. Alveolar epithelial cells actively transport electrolytes (Na ϩ and Cl Ϫ ) from the alveolar spaces to the interstitium, with corresponding movement of water through specialized water channels (aquaporins) (17) . Damage to epithelial and endothelial cells results in a major increase in lung permeability, and the alveolar spaces are flooded with a protein-rich exudate. Repair of the damaged alveolar epithelial membrane may involve fibrosis and sustained loss of gas exchange function in the lungs.
Epithelial Cell Apoptosis. In studies investigating the morphologic changes that occur in humans who die relatively early in the course of ARDS, Bachofen et al. (18) showed that type I pneumocytes are disrupted and reduced in size, with condensed nuclear chromatin. Subse-quent studies found evidence of DNA fragmentation in alveolar epithelial cells and increased expression of the bax gene, a bcl2 analog that favors apoptosis (19, 20) .Evidence of extensive alveolar epithelial cell apoptosis has been found in murine models of pulmonary fibrosis and endotoxin-induced lung injury (21) (22) (23) (24) (25) . Apoptosis of alveolar epithelial cells is detectable in mice as early as 6 hrs after the intratracheal administration of lipopolysaccharide (25) . Recent studies by Albertine et al. (26) showed that Fas expression is increased in the alveolar epithelium of patients who die with ARDS and that Fas ligand (FasL) is measurable in pulmonary edema fluids of patients with ALI. This confirms earlier observations (27).
Other Mechanisms of Epithelial Cell Death. Two mechanisms of alveolar epithelial cell death exist: apoptosis and necrosis. Alveolar epithelial apoptosis is likely to be a primary mechanism of lung epithelial cell death in patients with ALI, but necrosis of epithelial cells also needs to be explored.Shear forces caused by cyclic inflation and deflation of the lungs may contribute to disruption of cell membrane integrity and necrosis of the airway and alveolar epithelium (28). In experimental animals, mechanical ventilation with high tidal volumes causes hemorrhage and edema in isolated lungs and activates inflammatory pathways (29, 30 ). This process is referred to as ventilator-associated lung injury (31, 32). In humans, ventilation with lower tidal volumes is associated with a more rapid resolution of inflammatory responses in the lungs and improved survival (33, 34). The relative importance of shear stress and apoptosis in mediating alveolar epithelial death in the setting of ALI has yet to be clarified.
The Fas/FasL Pathway. Activation of the Fas/FasL pathway is relevant for apoptosis of the alveolar epithelium in humans and has been shown to be important in experimental models of lung injury. The Fas/FasL system consists of the Fas membrane receptor (CD95) and its natural ligand, FasL (35) . FasL exists in membrane-bound and soluble forms, both of which are capable of inducing apoptosis (27, 36) . FasL on lymphocytes interacts with CD95 on target cells to induce apoptosis, providing a mechanism for cell-mediated deletion of target cells. Alveolar and airway epithelial cells also express CD95 on their surfaces (37) (38) (39) , and the expression of Fas in epithelial cells increases in response to inflammatory mediators, such as bacterial endotoxin (22) .The soluble form of FasL (sFasL) has been detected in several human lung diseases, including pulmonary fibrosis, bronchiolitis obliterans with organizing pneumonia, and ARDS (27, 40, 41) . In humans with ARDS, sFasL is present in the BAL fluid and is at higher concentrations in the BAL fluid of patients who die (27). The sFasL detected in ARDS lung fluids is biologically active and can induce apoptosis of normal human lung epithelial cells derived from distal airways. Incubation of ARDS BAL fluids with specific inhibitors of FasL abolishes the apoptotic effect of ARDS BAL on human lung epithelial cells.
Accumulating evidence indicates that stimulation of Fas-dependent pathways in animal lungs causes alveolar epithelial apoptosis and lung injury. Recently, we have found that sFasL is released in lung fluids of mice with experimental pneumonia. Human sFasL induces apoptosis of rabbit type II pneumocytes, although studies with human type II pneumocytes have not been performed (42) . Instillation of human sFasL into the lungs of rabbits also causes alveolar hemorrhage and the production of proinflammatory cytokines, such as IL-8, by alveolar macrophages (42) .
Jo2. Instillation of a Fas-activating antibody (Jo2), which binds and activates membrane Fas, causes alveolar epithelial cell apoptosis, neutrophilic lung inflammation, and permeability increases in mice (36) . A single administration of Jo2 is followed at 6 hrs and 24 hrs by neutrophil recruitment and changes in alveolar protein permeability (36) . Repeated intratracheal administration of the Jo2 antibody for more than a week causes pulmonary fibrosis in mice, which is associated with DNA fragmentation in alveolar epithelial cells (43) .
Bleomycin. Treatment of mice with intratracheal bleomycin is associated with pulmonary fibrosis, which is significantly reduced by blockade of the Fas pathway by a specific antagonist (44) . Mice that lack active membrane Fas, due to a spontaneous genetic mutation (lpr mice), show only minimal pulmonary damage after bleomycin administration, further supporting the link between apoptosis and bleomycin-induced pulmonary fibrosis (44) .The weight of the experimental evidence in animals indicates that activation of the Fas/FasL pathway is associated with ALI, chronic lung injury with fibrosis, and the induction of acute neutrophilic inflammation that is mediated by C-X-C chemokines such as IL-8 and macrophage inflammatory protein-1␣ (36, 42) .
Modulation of the Fas Pathways. The biological activity of the Fas pathways is mediated by several factors in vivo.
Surfactant Protein A. Surfactant protein A is a major surfactant-associated protein with a role in host defense (45) . Surfactant protein A inhibits apoptosis of lung fibroblasts and type II pneumocytes in vitro by mechanisms that have not been clarified (46, 47) . In patients with ARDS, the concentration of surfactant protein A in BAL fluid is significantly reduced, and this could favor enhanced responses of epithelial cells to proapoptotic stimuli such as sFasL (48) .
Angiotensin II. Angiotensin (AT)-II is a second important modulator of the FasL system in the lungs. Epithelial cells interact with AT-II via the AT-II receptor, which is required for Fas-mediated apoptosis of alveolar epithelial cells in vitro (49) . In ARDS, the concentration of ATconverting enzyme, which converts AT-I to AT-II, is increased in the BAL fluid (50) .
TGF-␤. The cytokine TGF-␤ is involved in the pathogenesis of bleomycininduced lung injury in mice (51, 52) . TGF-␤ enhances the apoptotic response of human lung epithelial cells to sFasL in vitro and is detectable in the lungs of patients with fibrotic lung injury (53) .
Decoy Receptor 3. Finally, a specific inhibitor of apoptosis, decoy receptor 3, is detectable in lung BAL fluids (3, 54) . Decoy receptor 3 is a cell surface receptor, which is shed and acts as a soluble decoy for sFasL.Thus, at the onset of ALI, several different factors in BAL fluid could favor alveolar epithelial apoptosis. These include increased concentrations of sFasL; increased concentrations of TGF-␤, AT-converting enzyme, and AT-II; and decreased concentrations of surfactant protein A. In contrast, the accumulation of soluble decoy receptor 3 could inhibit the apoptotic activity of sFasL.
The balance between proapoptotic and antiapoptotic factors in the lungs may have an important role in determining the fate of the epithelium, analogous to the way in which the balance between cytokines and soluble antagonists modulates inflammatory activity in the lungs (55).
Summary and Conclusions
The pathways of apoptosis are likely to be important in humans with ALI, as well as in normal development and repair. The effects of apoptosis vary with cell type and with the time after onset of ALI: Neutrophil apoptosis is delayed in the lungs of patients with ALI, and this effect is mediated by GM-CSF and other soluble factors. sFasL accumulates in the airspaces of patients with ALI and is likely to mediate epithelial apoptosis in vivo. Shear forces generated by mechanical ventilation may cause direct necrosis of alveolar epithelial cells.
Fas-dependent pathways lead to inflammation by stimulating cytokine production by alveolar macrophages. Modulation of these pathways should provide new opportunities to limit epithelial damage and neutrophilic inflammation in the lungs of patients with ALI. dothelial 
